Pre-treatment with P2Y12 inhibitors in ACS patients: who, when, why, and which agent?
… Dual antiplatelet therapy (DAPT) with aspirin and a P2Y 12 receptor inhibitor is the
mainstay of treatment for acute coronary syndrome (ACS) patients, whether they undergo a …
mainstay of treatment for acute coronary syndrome (ACS) patients, whether they undergo a …
[HTML][HTML] Pre-Treatment With Oral P2Y12 Inhibitors in Acute Coronary Syndromes Without ST-Segment Elevation: The Saga Continues
D Capodanno, DJ Angiolillo - Journal of the American College of …, 2019 - jacc.org
… In invasively managed acute coronary syndromes (ACS), the term “pre-treatment” usually
refers to the practice of initiating dual antiplatelet therapy, in particular an oral P2Y 12 inhibitor …
refers to the practice of initiating dual antiplatelet therapy, in particular an oral P2Y 12 inhibitor …
[HTML][HTML] Short term outcome following acute phase switch among P2Y12 inhibitors in patients presenting with acute coronary syndrome treated with PCI: A systematic …
Introduction The efficacy and safety of switching P2Y 12 receptor antagonists in patients
admitted for acute coronary syndrome (ACS) remain unclear. We assessed the short-term …
admitted for acute coronary syndrome (ACS) remain unclear. We assessed the short-term …
High and low on-treatment platelet reactivity to P2Y12 inhibitors in a contemporary cohort of acute coronary syndrome patients undergoing percutaneous coronary …
JL Ferreiro, D Vivas, JM De La Hera, AL Marcano… - Thrombosis …, 2019 - Elsevier
… was observed at day 1 with the VerifyNow P2Y12 assay (51.5 ± 2.8 vs. 42.7 ± 3.5 PRUs; p
= 0.298), whereas ticagrelor achieved greater platelet inhibition at day 30 (48.1 ± 2.5 vs. 89.2 …
= 0.298), whereas ticagrelor achieved greater platelet inhibition at day 30 (48.1 ± 2.5 vs. 89.2 …
Assessment of pretreatment with oral P2Y12 inhibitors and cardiovascular and bleeding outcomes in patients with non-ST elevation acute coronary syndromes: a …
… Conclusions and Relevance In this study, pretreatment with oral P2Y12 inhibitors among
patients with NSTEACS prior to angiography, compared with treatment once coronary anatomy …
patients with NSTEACS prior to angiography, compared with treatment once coronary anatomy …
Reviewing the controversy surrounding pre-treatment with P2Y12 inhibitors in acute coronary syndrome patients
D Capodanno, DJ Angiolillo - Expert Review of Cardiovascular …, 2016 - Taylor & Francis
Pretreatment with oral P2Y 12 inhibitors occurs each time clopidogrel, prasugrel, ticagrelor
are given to patients with suspected coronary artery disease before definition of the coronary …
are given to patients with suspected coronary artery disease before definition of the coronary …
Meta-analysis comparing P2Y12 inhibitors in acute coronary syndrome
… a P2Y 12 -receptor inhibitor reduces atherothrombotic events following an acute coronary
syndromes (ACS), but the relative merits of different P2Y 12 inhibitors remain unclear, despite …
syndromes (ACS), but the relative merits of different P2Y 12 inhibitors remain unclear, despite …
What are optimal P2Y12 inhibitor and schedule of administration in patients with acute coronary syndrome?
MV Cohen, JM Downey - Journal of cardiovascular …, 2020 - journals.sagepub.com
Guidelines recommend treatment with a P2Y 12 platelet adenosine diphosphate receptor
inhibitor … The P2Y 12 inhibitor was initially used for its platelet anti-aggregatory action to block …
inhibitor … The P2Y 12 inhibitor was initially used for its platelet anti-aggregatory action to block …
Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials
… 12 inhibitors in acute coronary syndrome. We aimed to evaluate current evidence comparing
the efficacy and safety profile of prasugrel, ticagrelor, and clopidogrel in acute coronary …
the efficacy and safety profile of prasugrel, ticagrelor, and clopidogrel in acute coronary …
Real-world use of novel P2Y12 inhibitors in patients with acute myocardial infarction: a treatment paradox
… a more contemporary approach of treatment with a novel P 2 Y 12 inhibitor. While prasugrel
… , patients treated with clopidogrel compared to those treated with novel P 2 Y 12 inhibitors …
… , patients treated with clopidogrel compared to those treated with novel P 2 Y 12 inhibitors …
相关搜索
- meta analysis treatment with p2y12 inhibitors
- acute coronary syndrome p2y12 inhibitors
- st segment p2y12 inhibitors
- p2y12 inhibitor treatment percutaneous coronary intervention
- optimal p2y12 inhibitor
- acs patients p2y12 inhibitors
- treatment paradox p2y12 inhibitors
- systematic review treatment with p2y12 inhibitors
- clopidogrel in patients p2y12 inhibitors
- p2y12 inhibitor treatment short term
- p2y12 inhibitor treatment platelet reactivity
- acute myocardial infarction p2y12 inhibitors
- meta analysis of comparison p2y12 inhibitors